CINECA IRIS Institutional Research Information System

NOVELLO, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.555
EU - Europa 18.189
AS - Asia 16.605
SA - Sud America 756
OC - Oceania 639
AF - Africa 330
Continente sconosciuto - Info sul continente non disponibili 237
Totale 61.311
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.443
CN - Cina 8.412
IT - Italia 4.084
GB - Regno Unito 2.402
JP - Giappone 2.397
DE - Germania 1.727
IE - Irlanda 1.640
FR - Francia 1.489
IN - India 1.178
SE - Svezia 1.020
KR - Corea 983
ES - Italia 960
CA - Canada 902
VN - Vietnam 694
PL - Polonia 648
HK - Hong Kong 639
NL - Olanda 603
AU - Australia 558
UA - Ucraina 549
FI - Finlandia 538
TW - Taiwan 462
CH - Svizzera 429
TR - Turchia 418
BR - Brasile 399
AT - Austria 395
SG - Singapore 335
BE - Belgio 315
IL - Israele 220
DK - Danimarca 195
TH - Thailandia 187
RU - Federazione Russa 174
PT - Portogallo 171
GR - Grecia 170
MX - Messico 159
RO - Romania 134
AP - ???statistics.table.value.countryCode.AP??? 129
IR - Iran 105
NO - Norvegia 105
MY - Malesia 97
EU - Europa 96
ZA - Sudafrica 93
AR - Argentina 90
CZ - Repubblica Ceca 90
ID - Indonesia 88
PE - Perù 88
CO - Colombia 80
NZ - Nuova Zelanda 80
HU - Ungheria 75
EG - Egitto 67
PH - Filippine 64
CL - Cile 63
SA - Arabia Saudita 60
PK - Pakistan 58
JO - Giordania 49
RS - Serbia 42
SI - Slovenia 33
BG - Bulgaria 31
MA - Marocco 30
HR - Croazia 28
NG - Nigeria 28
SK - Slovacchia (Repubblica Slovacca) 24
LT - Lituania 23
MK - Macedonia 22
EC - Ecuador 19
IQ - Iraq 19
BD - Bangladesh 18
DZ - Algeria 17
CY - Cipro 16
LB - Libano 16
TN - Tunisia 16
MO - Macao, regione amministrativa speciale della Cina 15
BA - Bosnia-Erzegovina 14
ET - Etiopia 14
SN - Senegal 13
BY - Bielorussia 11
CR - Costa Rica 11
CU - Cuba 11
LV - Lettonia 11
MT - Malta 11
UY - Uruguay 11
UZ - Uzbekistan 11
LY - Libia 10
UG - Uganda 10
LK - Sri Lanka 9
AE - Emirati Arabi Uniti 8
AM - Armenia 8
GH - Ghana 8
DO - Repubblica Dominicana 7
KZ - Kazakistan 7
TJ - Tagikistan 7
GT - Guatemala 6
PA - Panama 6
SC - Seychelles 5
XK - ???statistics.table.value.countryCode.XK??? 5
AL - Albania 4
BO - Bolivia 4
EE - Estonia 4
IS - Islanda 4
KE - Kenya 4
LU - Lussemburgo 4
Totale 61.241
Salva come PNG Salva come JPEG
Città #
Beijing 2.133
Dublin 1.592
Chandler 1.576
Fairfield 1.430
Houston 1.329
Redwood City 1.138
Shanghai 913
Woodbridge 851
Torino 830
Ashburn 800
Wilmington 776
Duncan 660
Ann Arbor 654
Seattle 617
Tokyo 616
Cambridge 537
Princeton 524
Medford 464
Guangzhou 440
Pisa 425
Hangzhou 374
London 361
New York 358
Villeurbanne 354
Nanjing 351
Warsaw 345
Jacksonville 343
Nyköping 339
Taipei 324
Vienna 320
Turin 305
Dong Ket 297
Chengdu 255
Dearborn 241
Fremont 241
Jinan 231
Boston 228
Milan 227
Seoul 212
Zhengzhou 197
San Diego 176
Amsterdam 173
Madrid 171
Singapore 167
Toronto 164
Wuhan 164
Los Angeles 150
Sydney 146
Changsha 142
Central 140
Chicago 137
Paris 133
Rome 130
Ottawa 123
Mumbai 115
Central District 113
Philadelphia 113
Barcelona 109
Nutley 108
Hefei 102
Brussels 101
Santa Clara 101
Shenyang 101
Hebei 100
Düsseldorf 99
Manchester 97
Jerusalem 93
Tianjin 92
Hyderabad 91
Hanoi 90
Boardman 85
Fuzhou 85
Norwalk 84
Berlin 82
Munich 82
Chongqing 80
Zurich 78
Hong Kong 77
Atlanta 75
Delhi 75
São Paulo 75
San Francisco 74
San Jose 73
Osaka 72
Xian 72
Collegeville 69
Nanchang 69
Newbury Park 69
Bangkok 67
Bengaluru 67
Frankfurt am Main 67
Falls Church 66
Polska 66
Kunming 65
North Wales 65
Lima 64
Pune 63
Ho Chi Minh City 58
Istanbul 57
Birmingham 56
Totale 30.086
Salva come PNG Salva come JPEG
Nome #
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer 9.474
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer 4.358
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. 3.556
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. 3.303
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2.081
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer 1.514
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study 1.394
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s 1.218
Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer 784
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial 738
PARP inhibitors: an interesting pathway also for non-small cell lung cancer? 726
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial 628
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer 538
Extending survival of stage IV non-small cell lung cancer. 479
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis 476
Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled lume-meso trial 457
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 451
Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer? 432
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 428
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry 425
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial 370
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. 367
Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: A prospective study 363
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Results from a multicenter Italian observational study 351
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario 322
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma non-small cell lung cancer. 319
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study 313
Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer 307
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. 287
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. 285
Detection of EGFR mutations in archival lung cancer samples by pyrosequencing 283
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations 280
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 257
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. 255
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 255
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report 252
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. 246
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. 233
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker 227
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma 226
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 218
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 213
Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study 210
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. 198
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 191
ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. 189
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. 171
Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 170
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 167
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin 160
Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. 158
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer 158
Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 154
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018 153
Epidermal growth factor receptor tyrosine kinase inhibitors as adjuvant therapy in completely resected non-small-cell lung cancer 149
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer 142
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers 140
Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. 132
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer 132
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. 132
Fatigue in lung cancer patients: symptom burden and management of challenges. 130
Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer 128
Current state-of-the-art therapy for advanced squamous cell lung cancer 127
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer 126
Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. 126
Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era 126
Fetal adenocarcinoma of the lung in a 25-year-old woman 125
Tackling ALK in non-small cell lung cancer: The role of novel inhibitors 125
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 124
Clonal Heterogeneity in Non-Small Cell Lung Cancer and the Possible Role in Predicting Response to Treatment with Immune Checkpoint Inhibitors 124
Thymidylate synthase expression in large cell carcinoma ofthe lung 120
Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib. 120
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients 120
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. 114
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 114
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study 110
Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield 107
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 107
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 106
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer: A Phase-II Study. 106
First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era 106
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival 106
Trattamento del carcinoma polmonare in stadio avanzato. Dall’approccio classico alla medicina di precisione e prospettive future. 105
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine 105
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung 105
Clinical and biological significance of CD157 in malignant pleural mesothelioma 104
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases 102
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma 102
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial 101
Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread? 101
SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer 100
Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey 100
Diagnostica per immagini 99
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. 96
Incremental innovation and progress in advanced squamous cell lung cancer: current status and future impact of treatment. 96
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 96
Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup 94
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion 94
IκBα targeting promotes oxidative stress-dependent cell death 94
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study 93
Totale 46.979
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.511
article - articoli 0
book - libri 0
conference - conferenze 4.130
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.641
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.816 0 0 0 0 0 0 0 0 0 0 1.192 624
2019/20209.139 569 573 551 1.032 769 1.015 973 795 877 714 691 580
2020/202111.905 578 610 906 952 1.144 1.073 896 940 1.142 1.137 974 1.553
2021/202211.553 939 883 899 956 881 778 994 894 833 825 1.360 1.311
2022/202310.752 923 786 520 920 876 1.922 894 889 1.071 519 764 668
2023/20247.813 992 1.086 712 785 733 772 869 884 183 742 55 0
Totale 63.523